Skip to main content
Livermore
Livermore
ZHEN

Crescent Biopharma, Inc.

CBIO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001253689

In the last 90 days, Crescent Biopharma, Inc. insiders filed 1 open-market purchase and 7 sales; 82 institutions reported holding it in 13F filings for Q2 2026, worth $532.6M in total; no superinvestor holds it.

Holders of 5% or more of CBIO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Crescent Biopharma, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of CBIO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Fairmount Funds Management LLC13D/A16.52%6.60M shares−2.01 ppfrom 18.53%Jun 23, 20253 filingsJul 20, 2026SEC
FMR LLC13G/A15.00%4.13M shares+4.80 ppfrom 10.20%Jul 8, 20252 filingsFeb 5, 2026SEC
1Globe Capital LLC13G/A10.30%1.43M shares+3.85 ppfrom 6.45%Aug 20, 20252 filingsOct 14, 2025SEC
Biotechnology Value Fund L P13G/A9.99%1.39M shares–Feb 11, 20213 filingsAug 14, 2025SEC
Venrock Healthcare Capital Partners III, L.P.13G/A9.50%2.67M shares−0.40 ppfrom 9.90%Jun 23, 20252 filingsFeb 17, 2026SEC
ForGrowth III PA B.V.13G6.10%1.68M sharesNewDec 11, 20251 filingDec 11, 2025SEC
Balyasny Asset Management LLC13G/A6.03%1.66M shares+0.55 ppfrom 5.48%May 15, 20262 filingsAug 14, 2026SEC
Vestal Point Capital, LP13G5.40%1.50M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

41 Schedule 13D and 13G filings on Crescent Biopharma, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CBIO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 14, 20266:01 AM ETBalyasny Asset Management LLCand 4 others13G/A6.03%1.66M shares+0.55 ppfrom 5.48%Jun 30, 2026SEC
Jul 20, 20265:30 PM ETFairmount Funds Management LLCand 3 others13D/A16.52%6.60M shares−2.01 ppfrom 18.53%Jul 16, 2026SEC
May 15, 20264:15 PM ETTang Capital Management LLCand 5 others13G/A4.21%1.16M shares−0.83 ppfrom 5.04%Below 5%Mar 31, 2026SEC
May 15, 20266:31 AM ETBalyasny Asset Management LLCand 4 others13G5.48%1.51M sharesNewMar 31, 2026SEC
Feb 17, 20266:05 PM ETVenrock Healthcare Capital Partners III, L.P.and 6 others13G/A9.50%2.67M shares−0.40 ppfrom 9.90%Dec 31, 2025SEC
Feb 17, 20264:06 PM ETVestal Point Capital, LPand 1 other13G5.40%1.50M sharesNewDec 31, 2025SEC
Feb 5, 20261:20 PM ETFMR LLCand 1 other13G/A15.00%4.13M shares+4.80 ppfrom 10.20%Dec 31, 2025SEC
Dec 11, 20254:00 PM ETForGrowth III PA B.V.and 2 others13G6.10%1.68M sharesNewDec 8, 2025SEC
Dec 8, 20254:30 PM ETFairmount Funds Management LLCand 3 others13D/A18.53%5.64M shares−1.46 ppfrom 19.99%Dec 4, 2025SEC
Oct 14, 20253:41 PM ET1Globe Capital LLCand 1 other13G/A10.30%1.43M shares+3.85 ppfrom 6.45%Oct 7, 2025SEC
Oct 9, 20254:15 PM ETTang Capital Management LLCand 5 others13G5.04%700.0K sharesNewOct 2, 2025SEC
Aug 20, 20255:20 PM ET1Globe Capital LLCand 1 other13G6.45%896.7K sharesNewAug 13, 2025SEC
Aug 14, 20254:01 PM ETBiotechnology Value Fund L Pand 9 others13G/A9.99%1.39M shares–Jun 30, 2025SEC
Aug 14, 20252:24 PM ETLogos Global Management LPand 4 others13G/A4.10%575.0K shares–Below 5%Jun 30, 2025SEC
Jul 8, 20259:07 AM ETFMR LLCand 1 other13G10.20%1.41M sharesNewJun 30, 2025SEC
Jun 23, 20256:32 PM ETFairmount Funds Management LLCand 3 others13D19.99%3.12M sharesNewJun 13, 2025SEC
Jun 23, 20254:30 PM ETVenrock Healthcare Capital Partners III, L.P.and 6 others13G9.90%1.39M sharesNewJun 13, 2025SEC
Jun 20, 20254:05 PM ETAdage Capital Management, L.P.and 2 others13D/A0.37%50.9K shares–Below 5%Jun 20, 2025SEC
Feb 14, 20256:38 PM ETRa Capital Management, L.P.and 3 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Nov 27, 2024Logos Global Management LP13GOld format–New–SEC
Nov 12, 2024Invus Global Management, LLC13G/AOld format–––SEC
Nov 6, 2024Ra Capital Management, L.P.13GOld format–New–SEC
Nov 4, 20242:01 PM ETWeinstein Benjamin13G/A0.10%50.0K shares−5.20 ppfrom 5.30%Below 5%Oct 30, 2024SEC
Nov 4, 2024Adage Capital Management, L.P.13DOld format–New–SEC
Aug 15, 2024Invus Global Management, LLC13G/AOld format–––SEC
Aug 14, 20244:13 PM ETWeinstein Benjamin13G5.30%3.40M sharesNewAug 9, 2024SEC
Jul 29, 2024Invus Global Management, LLC13G/AOld format–––SEC
May 8, 2024New Enterprise Associates 10 L P13D/AOld format–––SEC
Feb 29, 2024New Enterprise Associates 10 L P13D/AOld format–––SEC
Feb 12, 2024New Enterprise Associates 10 L P13D/AOld format–––SEC
Feb 9, 2024Artal International S.C.A.13G/AOld format–––SEC
Jan 29, 2024Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 13, 2023Artal International S.C.A.13GOld format–New–SEC
Feb 10, 2023New Enterprise Associates 10 L P13D/AOld format–––SEC
Feb 10, 2022Vanguard Group Inc13G/AOld format–––SEC
Jul 12, 20218:29 AM ETBlackRock Inc.13G/AOld format–––SEC
Feb 16, 2021Camber Capital Management LP13G/AOld format–––SEC
Feb 12, 2021EcoR1 Capital, LLC13G/AOld format–––SEC
Feb 11, 2021Biotechnology Value Fund L P13G/AOld format–––SEC
Feb 10, 2021Vanguard Group Inc13GOld format–New–SEC
Jan 29, 20219:57 AM ETBlackRock Inc.13G/AOld format–––SEC

Form 144: proposed insider sales

1 notice from officers, directors and other affiliates planning to sell Crescent Biopharma, Inc. shares, newest first.

Form 144 notices for CBIO
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
May 17, 202311:11 AM ETHahn Brian M.Officer4.31K$8.45KMay 17, 2023Merrill LynchSEC